Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

被引：0
|
作者：
Jeeyun Lee
Kyung Hae Jung
Young Suk Park
Joong Bae Ahn
Sang Jun Shin
Seock-Ah Im
Do Youn Oh
Dong Bok Shin
Tae Won Kim
Namsu Lee
Jae Ho Byun
Yong Sang Hong
Joon Oh Park
Se Hoon Park
Ho Yeong Lim
Won Ki Kang
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Research Institute and Hospital,Oncology, Department of Medicine, Samsung Medical Center
[3] Yonsei University College of Medicine,Center for Colorectal Cancer, National Cancer Center
[4] Seoul National University College of Medicine,Department of Internal Medicine
[5] Gachon University Gil Medical Center,Department of Internal Medicine
[6] University of Ulsan College of Medicine,Division of Hematology and Oncology, Department of Internal Medicine
[7] Soon Chun Hyang University Hospital,Division of Oncology, Department of Medicine, Asan Medical Center
[8] The Catholic University of Korea,Division of Hematology
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Statin; Simvastatin; Irinotecan; Cetuximab; Lovastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：657 / 663
页数：6
相关论文
共 50 条
  • [11] A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
    Sym, Sun Jin
    Hong, Junshik
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Park, Yeon Ho
    Lee, Woon Ki
    Chung, Min
    Kim, Hyung-Sik
    Park, Se Hoon
    Shin, Dong Bok
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 481 - 488
  • [12] Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
    Kotake, Masanori
    Aoyama, Toru
    Munemoto, Yoshinori
    Doden, Kenji
    Kataoka, Masato
    Kobayashi, Kenji
    Nishimura, Genichi
    Fujita, Hidehito
    Nakamura, Keishi
    Takehara, Akira
    Tanaka, Chihiro
    Sakamot, Junichi
    NagatA', Naoki
    Oba, Koji
    Kondo, Ken
    ONCOLOGY LETTERS, 2017, 13 (02) : 747 - 753
  • [13] Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study
    Eric François
    Jean-François Berdah
    Emmanuel Chamorey
    Gérard Lesbats
    Eric Teissier
    Jean-François Codoul
    Jean-Luc Badetti
    Christophe Hébert
    Véronique Mari
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 931 - 936
  • [14] Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer:: a Phase II study
    Francois, Eric
    Berdah, Jean-Francois
    Chamorey, Emmanuel
    Lesbats, Gerard
    Teissier, Eric
    Codoul, Jean-Francois
    Badetti, Jean-Luc
    Hebert, Christophe
    Mari, Veronique
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (06) : 931 - 936
  • [15] First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule
    Masi, G
    Allegrini, G
    Cupini, S
    Marcucci, L
    Cerri, E
    Brunetti, I
    Fontana, E
    Ricci, S
    Andreuccetti, M
    Falcone, A
    ANNALS OF ONCOLOGY, 2004, 15 (12) : 1766 - 1772
  • [16] Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer
    Kono, T
    Ebisawa, Y
    Tomita, I
    Chisato, N
    Kamiya, K
    Asama, T
    Ayabe, T
    Ashida, T
    Kohgo, Y
    Kasai, S
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (02) : 224 - 227
  • [17] Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
    Andreas Teufel
    Silke Steinmann
    Jürgen Siebler
    Christiane Zanke
    Herbert Hohl
    Bernd Adami
    M Schroeder
    O Klein
    Thomas Höhler
    Peter R Galle
    Michael Heike
    Markus Moehler
    BMC Cancer, 4
  • [18] Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A. Meyerhardt
    Jeffrey W. Clark
    Jeffrey G. Supko
    Joseph P. Eder
    Shuji Ogino
    Clinton F. Stewart
    Ferdinando D’Amato
    Janet Dancey
    Peter C. Enzinger
    Andrew X. Zhu
    David P. Ryan
    Craig C. Earle
    Robert J. Mayer
    Ann Michelini
    Kate Kinsella
    Charles S. Fuchs
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 661 - 670
  • [19] Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study
    Iwamoto, Shigeyoshi
    Hazama, Shoichi
    Kato, Takeshi
    Miyake, Yasuhiro
    Fukunaga, Mutsumi
    Matsuda, Chu
    Bando, Hiroyuki
    Sakamoto, Junichi
    Oba, Koh
    Mishima, Hideyuki
    ANTICANCER RESEARCH, 2014, 34 (04) : 1967 - 1973
  • [20] A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer
    Pan, CX
    Loehrer, P
    Seitz, D
    Helft, P
    Juliar, B
    Ansari, R
    Pletcher, W
    Vinson, J
    Cheng, L
    Sweeney, C
    ONCOLOGY, 2005, 69 (01) : 63 - 70
12345